$SNEX

OCONNOR SEAN MICHAEL sold $20.0M of SNEX

OCONNOR SEAN MICHAEL (Executive Vice-Chairman-Board) sold 150,000 shares of StoneX Group Inc. (SNEX) at an average of $133.29 ($131.15–$135.42, $19.99M total) across 2 trades over 2026-06-12 to 2026-06-15.

Original reporting
SEC EDGAR · OCONNOR SEAN MICHAEL
Published Jun 16, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Neutral
medium confidence
Mentioned
$SNEX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralLow
01

Why it matters

A director/executive vice-chairman sold 150,000 shares across two trades at ~$131.15–$135.42, totaling ~$19.99M, with no pre-arranged 10b5-1 plan indicated.

02

Market read

Traders may monitor SNEX for sentiment drift after a large insider sale, but the disclosure lacks fundamental catalysts.

03

What to watch

The filing does not state tax, diversification, or personal liquidity needs; traders should weigh this against SNEX’s recent fundamentals and any concurrent news not included here.

Relevance 7/10Novelty 6/10Timing: Filed today (2026-06-16) covering sales from 2026-06-12 to 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for StoneX Group Inc. (SNEX).

Company-level read

Ticker impact

$SNEXNeutralMedium confidence
Context

StoneX Group insider OCONNOR Sean Michael sold ~$20.0M of SNEX shares in open-market trades (Form 4).

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader tape/earnings context.

Evidence & confidence

The filing discloses transaction size, dates, and lack of a pre-arranged 10b5-1 plan, which can influence perception, but provides no new operating or guidance information.

Market effects

Minimal; this is company-specific insider activity with no disclosed sector-wide catalyst.

Minimal; no geographic or cross-border operational change disclosed.

Minimal; no global deal/regulatory development mentioned.

Counterpoint

Insider sales can be routine liquidity/portfolio rebalancing; the absence of a stated 10b5-1 plan does not prove negative fundamentals.

Key entities

  • StoneX Group Inc.

    Subject of the Form 4 insider sale disclosure.

  • OCONNOR Sean Michael

    Executive Vice-Chairman of the Board who sold SNEX shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.